Wakelee H - Search Results

1

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.

Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H, Diehn M. Jeong Y, et al. Among authors: wakelee h. Clin Cancer Res. 2020 Jan 1;26(1):274-281. doi: 10.1158/1078-0432.CCR-19-1237. Epub 2019 Sep 23. Clin Cancer Res. 2020. PMID: 31548347 Free PMC article.

2

Docetaxel in advanced non-small cell lung cancer.

Wakelee H, Ramalingam S, Belani CP. Wakelee H, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):13-24. doi: 10.1586/14737140.5.1.13. Expert Rev Anticancer Ther. 2005. PMID: 15757434 Review.

3

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.

Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH; Eastern Cooperative Oncology Group. Wakelee HA, et al. Lung Cancer. 2005 Jun;48(3):389-97. doi: 10.1016/j.lungcan.2004.11.007. Epub 2005 Jan 5. Lung Cancer. 2005. PMID: 15893008 Clinical Trial.

4

Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.

Wakelee HA, Sikic BI. Wakelee HA, et al. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S6-12. doi: 10.3816/clc.2005.s.002. Clin Lung Cancer. 2005. PMID: 16159420 Review.

5

Second- and third-line treatments in non-small cell lung cancer.

Kumar A, Wakelee H. Kumar A, et al. Among authors: wakelee h. Curr Treat Options Oncol. 2006 Jan;7(1):37-49. doi: 10.1007/s11864-006-0030-9. Curr Treat Options Oncol. 2006. PMID: 16343367 Review.

6

Optimizing first-line treatment options for patients with advanced NSCLC.

Wakelee H, Belani CP. Wakelee H, et al. Oncologist. 2005;10 Suppl 3:1-10. doi: 10.1634/theoncologist.10-90003-1. Oncologist. 2005. PMID: 16368866 Free article. Review.

7

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ. Le QT, et al. Among authors: wakelee h. Clin Cancer Res. 2006 Mar 1;12(5):1507-14. doi: 10.1158/1078-0432.CCR-05-2049. Clin Cancer Res. 2006. PMID: 16533775 Free article.

8

Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.

Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Wakelee HA, et al. Cancer. 2006 May 15;106(10):2208-17. doi: 10.1002/cncr.21869. Cancer. 2006. PMID: 16604529 Free article.

9

Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.

Wakelee HA, Schiller JH, Gandara DR. Wakelee HA, et al. Clin Lung Cancer. 2006 Jul;8(1):18-21. doi: 10.3816/CLC.2006.n.028. Clin Lung Cancer. 2006. PMID: 16870041 Review.

10

A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma.

Roy MS, Le QT, Donington JS, Wakelee HA. Roy MS, et al. Clin Lung Cancer. 2006 Sep;8(2):146-8. doi: 10.3816/CLC.2006.n.044. Clin Lung Cancer. 2006. PMID: 17026817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

343 results

Search Page